The MRC/UVRI and LSHTM Uganda Research Unit has unveiled a new state-of-the-art clinical research facility in Entebbe to further boost its contributions to science, policy and practice in Uganda.
MRC/UVRI and LSHTM Uganda Research Unit unveils new facility to research infectious and non-communicable diseases miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The facility commissioning ceremony was presided over by the Hon. Dr. Jane Ruth Aceng, the Minister of Health, and attended by Her Excellency Kate Airey OBE, the British High Commissioner to Uganda, and Professor Liam Smeeth, the Director of the London School of Hygiene & Tropical Medicine. Funded by Wellcome and the UKRI United Kingdom Research and Innovation/Medical Research Council, the solar-powered facility will be used to conduct clinical research in infectious and non-communicable diseases.
Informed consent isn’t as simple as getting verbal or written consent from a participant one time. Rather, it is the start of an ongoing relationship based on communication.
By Medidata, a Dassault Systèmes company
The pandemic drove 45% of clinical trial sites to transition patients from in-person to remote visits using virtual trial solutions.¹ An astounding 83% of all clinical trials are now partially or entirely virtualized,¹ with components taking place and being managed from outside the traditional trial site setting.
While adopting new virtualization technologies introduces new challenges and learning curves, it also creates significant opportunities for all stakeholders. In fact, an estimated 97% of biopharma executives intend to leverage digital technologies in clinical trials over the next three years.²
To alleviate some of the many stressors on patients, sites, and sponsors adjusting to the new virtual clinical trial setting, adoption of the right support services can be a strong complement. Partnering with technology specialists to design, deploy, or outsource virtual trials not only helps accelerate the adoption of virtual capabilit